Frontera Therapeutics, A Global Clinical-Stage Biotechnology Company, Announced That It Has Dosed The First Patient In A Phase 1 Clinical Trial Of Its Lead Gene Therapy Programme, Ft-001, For The Treatment Of Leber Congenital Amaurosis-2, A Severe Inherited Retinal Disease Related To A Mutation In The Rpe65 Gene. Ft-001 Is Administered By A One-Time Injection Into The Subretinal Space Of The Eye That Delivers A Functional Copy Of The Human Rpe65 Gene To The Nuclei Of The Patient
